Tang Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Tang Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$10.8M	–	57
2025 Q4	$10.8M	Buy	+200,000	New	+$9.62M	0.53%	37
2020 Q1	–	Sell	-111,844	Closed	-$7.18M	–	26
2019 Q4	$7.18M	Buy	+111,844	New	+$6.41M	0.86%	10

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tang Capital Management's BMY Position: Q1 2026 in Review

Tang Capital Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 200,000 shares — an estimated $10.8M sold.

Tang Capital Management first reported a position in BMY in Q4 2019 and held it in 2 quarters. The position peaked at $10.8M in Q4 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Tang Capital Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Tang Capital Management sold 200,000 Bristol-Myers Squibb shares in Q1 2026, an estimated $10.8M.
Tang Capital Management first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 2 quarters.
Tang Capital Management's Bristol-Myers Squibb position peaked at $10.8M in Q4 2025.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.